Literature DB >> 35667076

In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.

Aditya Shah1, John C O'Horo1.   

Abstract

SOURCE CITATION: Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327-36. 35123660.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35667076     DOI： 10.7326/J22-0033

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   51.598


  1 in total

1.  Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Alexander P J Vlaar; Martin Witzenrath; Pieter van Paassen; Leo M A Heunks; Bruno Mourvillier; Sanne de Bruin; Endry H T Lim; Matthijs C Brouwer; Pieter R Tuinman; José F K Saraiva; Gernot Marx; Suzana M Lobo; Rodrigo Boldo; Jesus A Simon-Campos; Alexander D Cornet; Anastasia Grebenyuk; Johannes M Engelbrecht; Murimisi Mukansi; Philippe G Jorens; Robert Zerbib; Simon Rückinger; Korinna Pilz; Renfeng Guo; Diederik van de Beek; Niels C Riedemann
Journal:  Lancet Respir Med       Date:  2022-09-07       Impact factor: 102.642
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.